Septerna Inc., a clinical-stage biotechnology company, has announced plans to present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27-March 2, 2026, in Philadelphia. SEP-631 is a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator, being developed for the treatment of chronic spontaneous urticaria and other mast cell-driven diseases. The results from the first-in-human, proof-of-mechanism study will be shared during a late breaking poster session on March 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651613-en) on February 10, 2026, and is solely responsible for the information contained therein.